Real-world study on Tongxinluo's treatment of acute myocardial infarctio

Phase 4

Recruiting

• Conditions: Acute myocardial infarction

• Registration Number: ITMCTR2100005609
• Lead Sponsor: Hebei Yiling Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) Over 18 years old;
(2) The onset of infarct chest pain is within 24 hours;
(3) ST-segment elevation in more than 2 adjacent leads of ECG >=0.2mV, or new left bundle branch block;
(4) Volunteer to participate in this research and have signed an informed consent form;

Exclusion Criteria

(1) Because STEMI is already in critical condition;
(2) Patients who have undergone cardiopulmonary resuscitation for a long time (more than 20 minutes);
(3) Suspected aortic dissection or acute pulmonary embolism;
(4) Patients with clear mechanical complications (including perforation of the ventricular septum, or rupture of the papillary tendon bundle, or the free wall of the left ventricle is being or has been ruptured);
(5) Severe cardiogenic shock and no response to blood pressure drugs;
(6) Patients with uncontrolled acute left heart failure and pulmonary edema;
(7) Patients with malignant arrhythmias that are difficult to control with drugs;
(8) Patients who have had a history of hemorrhage in the cerebrovascular, gastrointestinal tract, respiratory tract, urinary tract or other organs in the past month;
(9) Patients who still have active bleeding in any part (including menstrual period);
(10) Patients with known bleeding constitution, or severe hemostatic and coagulation dysfunction;
(11) Patients who are taking therapeutic doses of anticoagulants (such as warfarin or new anticoagulants);
(12) Severe chronic obstructive pulmonary disease (COPD) or respiratory failure;
(13) Patients with neuropsychiatric diseases;
(14) Patients with malignant tumors;
(15) Patients who are allergic to the ingredients in this study;
(16) Pregnant or lactating women;
(17) Patients who are participating in other clinical studies;
(18) Patients with other diseases that are not suitable for participating in clinical research.

Study & Design

• Study Type: Observational study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Major adverse cardiovascular and cerebrovascular events (cardiovascular death, resuscitation, emergency coronary revascularization, stroke) rate;

Secondary Outcome Measures

Name	Time	Method
All-cause mortality;Compound endpoint event rate(MACCE, re-admission for heart failure, severe bleeding (BARC III and V));